Skip to content
ClinCalc Pro
Menu
Intranasal Corticosteroid

Beclometasone Dipropionate Nasal Spray

Brand names: Beconase, Pollenase

Used in: COPD

Beclometasone dipropionate nasal spray is a topical intranasal corticosteroid used to prevent and treat the symptoms of seasonal and perennial allergic rhinitis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Delivered locally to the nasal mucosa, it acts on glucocorticoid receptors to suppress inflammatory mediators and reduce mucosal inflammation, oedema and hypersecretion.

Prescribing in practice

  • Direct the spray slightly outward, away from the nasal septum, and review with prolonged use, as local irritation, crusting, epistaxis and rarely nasal septal perforation can occur.
  • Maximum benefit develops over days of regular use, so it should be taken continuously rather than as required.
  • Systemic absorption is low at recommended doses, but prolonged or high-dose intranasal corticosteroid use warrants attention to cumulative steroid burden, particularly in children where growth should be monitored.

Monitoring

Inspect the nasal mucosa periodically with prolonged use and monitor growth in children on long-term therapy.

Counselling the patient

  • Use it every day, as it works by preventing inflammation and takes a few days to reach full effect.
  • Aim the nozzle slightly towards the outer wall of the nostril, not the central wall, to reduce nosebleeds.
  • Report persistent nosebleeds, crusting or nasal discomfort to your team.

Evidence & guidelines

NICE and allergy guidelines recommend intranasal corticosteroids as the most effective single therapy for moderate-to-severe allergic rhinitis.

Reference: BSACI Rhinitis Guidelines 2017; NICE NG28 (Sinusitis); SIGN 134; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.